Detalhe da pesquisa
1.
Neuroendocrine Tumors: a Relevant Clinical Update.
Curr Oncol Rep
; 24(6): 703-714, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35254612
2.
Epidemiological risk factors for adrenocortical carcinoma: A hospital-based case-control study.
Int J Cancer
; 146(7): 1836-1840, 2020 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31241762
3.
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
Anticancer Drugs
; 31(3): 216-222, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31977567
4.
Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Oncologist
; 24(4): 463-474, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30355775
5.
Stereotactic body radiation therapy and immunotherapy.
Clin Adv Hematol Oncol
; 17(9): 518-523, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31549973
6.
Molecular pathways and targeted therapy in cholangiocarcinoma.
Clin Adv Hematol Oncol
; 17(11): 630-637, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31851165
7.
BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS.
Endocr Pract
; 2018 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30084687
8.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
N Engl J Med
; 371(3): 224-33, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25014687
9.
Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol
; 15(11): 1791-1799, 2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28579181
10.
Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
Clin Adv Hematol Oncol
; 15 Suppl 4(4): 1-24, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28654022
11.
Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma.
Gastroenterology
; 149(1): 119-29, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25836985
12.
Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
Lancet Oncol
; 16(6): 695-703, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25956795
13.
New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
Clin Adv Hematol Oncol
; 13(5 Suppl 5): 1-18; quiz 1 p following 18, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26430956
14.
Impact of ¹8F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients.
Eur J Nucl Med Mol Imaging
; 41(11): 2066-73, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24990404
15.
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
BMC Cancer
; 14: 561, 2014 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25086465
16.
Treatment Patterns of Long-Acting Somatostatin Analogs for Neuroendocrine Tumors.
J Health Econ Outcomes Res
; 10(2): 121-131, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38093906
17.
Emerging treatment options for patients with gastroenteropancreatic neuroendocrine tumors.
Clin Adv Hematol Oncol
; 15 Suppl 4(4): 10-14, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28654024
18.
Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: Discussion.
Clin Adv Hematol Oncol
; 15 Suppl 4(4): 18-19, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28654026
19.
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
Endocrine
; 71(2): 502-513, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33052555
20.
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
Ann Surg Oncol
; 17(1): 263-70, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19851811